Yesterday
IFM Investors-backed healthtech drafts in RBC, E&P for float
It is understood the two brokers have been mandated to prepare Genie Solutions for life on the ASX boards.
- Sarah Thompson, Anthony Macdonald and Tim Boyd
This Month
ResMed swoops on rival’s stumble
Netherlands-based Philips has a $394 million problem with the recall of its DreamStation, but supply chain pressure could hamper ResMed’s attempts to capitalise.
- Carrie LaFrenz
Biogen’s colossal risk on Alzheimer’s pays off
The pharmaceutical group poured years of effort into developing the therapy, called aducanumab, and was counting on it as its next big advance.
- Updated
- Robert Langreth
Myer family-backed Cogstate jumps 60pc on Alzheimer’s news
Cogstate shares jumped 60 per cent by midday because its brain health screening tests will benefit from the approval of the first every Alzheimer’s treatment drug in the United States.
- Carrie LaFrenz
Finger-prick diagnostics company set for $188m IPO
Lumos Diagnostics is set to list on the ASX, raising $63 million, having already secured funds like Ellerston and Perennial as supporters.
- Yolanda Redrup
Health researchers step on the gas on many fronts
Experts say the pandemic has reinforced just how crucial cutting-edge research is in health and medicine.
- Simon Evans
Alzheimer’s drug approved in disease landmark
A controversial antibody therapy developed by Biogen was granted accelerated approval by the US Food and Drug Administration.
- Robert Langreth
Trajan IPO climbs in ASX debut
The analytical science and devices company chaired by rugby legend John Eales jumped 16.5 per cent on its first day of trade, pushing its market value to $256 million.
- Carrie LaFrenz
Younger women behind botox boom at Silk Laser Clinics
Personal grooming is a priority for the group’s 18-to-49-year-old customer base during the coronavirus pandemic.
- Simon Evans
Japara grants suitor access to its books
Calvary Healthcare will take a look under the hood of the listed aged care player after it upped its all-cash indicative offer to $1.20 per share.
- Carrie LaFrenz
Genomics company myDNA mulls US SPAC listing
The Melbourne-founded group’s goal is to empower consumers to unlock the data in their DNA to personalise everyday health decision-making.
- Carrie LaFrenz
Cancer testing biz BCAL launches IPO; targets July listing
Breast cancer detection company BCAL Diagnostics is turning to public markets to fast track the development of its diagnostic testing product.
- Sarah Thompson, Anthony Macdonald and Tim Boyd
Cartel case loss exposes holes in ACCC banking prosecution
Experts warn the competition watchdog’s resounding defeat in its first contested criminal cartel prosecution does not bode well for its landmark banking cartel trial next year.
- Hannah Wootton and Michael Pelly
Australia ‘too exposed to global drug supply shocks’
Importing more than 90 per cent of vital medicines is neither economically wise nor in Australia’s national security interest, says Arrotex Pharmaceuticals CEO Dennis Bastas.
- Carrie LaFrenz
ACL shares climb 5pc after profit upgrade
Shares of the nation’s third-largest pathology player climbed 19¢ on Thursday after it lifted full-year net profit guidance by 10 per cent to 15 per cent.
- Carrie LaFrenz
Still plenty of smoke in the vaping wars
The relationship between the nation’s small retailers and the local outfits of the world’s international tobacco giants appears closer than ever.
- Myriam Robin
May
Ellerston, Perennial help cornerstone Lumos Diagnostics’ $60m IPO
Blood testing technology business Lumos Diagnostics is ready for a big test of its own.
- Sarah Thompson, Anthony Macdonald and Tim Boyd
Cochlear taps Alison Deans as its new chairman
The former CEO of eBay Australia will take over from outgoing chairman Rick Holliday-Smith on August 21.
- Carrie LaFrenz
Ramsay boss picks his UK moment
The £1 billion cash bid for all the equity in Spire Healthcare came four years after the target rejected another bidder.
- Updated
- Carrie LaFrenz
Ramsay bets on volume surge in COVID-19-hit UK
Two brokers raised their price targets for the private hospitals operator after its deal to buy a UK-based rival was revealed, but the shares fell 3 per cent.
- Updated
- Carrie LaFrenz
